Navigation Links
Verinata Health Announces New Corporate Headquarters and Expanded Laboratory Operations
Date:12/7/2011

REDWOOD CITY, Calif., Dec. 7, 2011 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced the relocation of its corporate headquarters and laboratory operations to 800 Saginaw Drive, Redwood City, California.

"Our move to a much larger and state-of-the art facility is a demonstration of our commitment to appropriately prepare for the growth and expansion expected with the launch of our first product," said Caren L. Mason, Chief Executive Officer of Verinata.  "We have designed a clinical laboratory with initial capacity of over 150,000 tests annually.  In addition, we have expanded our R&D laboratory substantially, with further expansion opportunities available for both clinical and research space. Our corporate headquarters is also designed to uniquely and distinctively support our physician, patient, and payer support teams to provide the education, training and support services for our laboratory developed test."

Ms. Mason continued, "We are pleased to report that our non-invasive prenatal test for multiple chromosomal abnormalities remains on track for commercial launch in the first quarter of 2012."

Verinata Health, Inc.

Verinata is driven by a sole, extraordinary purpose – maternal and fetal health.  Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities using our proprietary technologies.  We aim to reduce the anxiety associated with today's multi-step process, the unacceptable false-positive rates, the non-specific and sometimes confusing results of current prenatal screening methods, as well as the risk of current invasive procedures. In support of national guidelines recommending first trimester aneuploidy risk assessment, we believe women who desire such an assessment should be offered a single blood draw test with a definitive result.  Verinata is conducting a prospective, blinded pivotal study to clinically validate the sensitivity and specificity of its first prenatal test on a large scale with results of the study expected in 2011. For more information about Verinata, please go to www.verinata.com.

 


'/>"/>
SOURCE Verinata Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Verinata Health Announces a Multi-Year Supply Agreement with Illumina in the Field of Non-Invasive Prenatal Diagnostics
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
4. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Tone Deafness Explained, from the Harvard Health Letter
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
9. ViroPharma to Present at Three Upcoming Healthcare Conferences
10. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... and PUNE, India , January 18, ... Allied Market Research, titled, "Breast Imaging Technologies Market by Type: ... global breast imaging technologies market size was valued at $2,544 ... by 2022, growing at a CAGR of 8.4% from 2016 ... Europe together accounted for over three-fourths market ...
(Date:1/18/2017)... Philadelphia Pediatric Medical Device Consortium (PPDC) has announced seed grants ... Consortium chose those companies from eight finalists in a ... The devices under development are a powered orthotic arm brace ... system for emergency situations and a device that gradually corrects ... ...
(Date:1/18/2017)... , Jan. 18, 2017   Spotlight ... subsidiary Caretta Therapeutics plans, in the second quarter ... a topical roll-on intended to provide relief from ... and steroidal analgesics. It was developed under a ... to commercialize products derived from snake venom. Additionally, ...
Breaking Medicine Technology:
(Date:1/19/2017)... , ... January 19, 2017 , ... Infinity® Massage Chairs ... plan and implement new sales and marketing strategies. Grover comes with a total of ... 5 and a half years as Executive Vice President of Direct Sales at Traeger® ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Osteopathic College of Proctology) announced today the opening of 3 medical offices ... http://www.hemorrhoidsremovalcenterscalifornia.com ): Hemorrhoids Center of Los Angeles (Beverly Hills), Hemorrhoids Center of ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... A recent ... opened a global discussion about the benefits of fidgeting to relieve stress and anxiety. ... Jym Daniel. Their Think Ink Pen had just completed a successful Kickstarter campaign ...
(Date:1/18/2017)... Charlottesville, Virginia (PRWEB) , ... January 18, 2017 , ... ... New studies are released almost daily linking gut health to chronic disease, mental health ... the New Year ” as an important resolution to consider. , For one Charlottesville ...
(Date:1/18/2017)... ... January 18, 2017 , ... The VA ... are collaborating on a research project focused on multiple sclerosis (MS). Led by ... use nanotechnology to control the disease without compromising normal immune function that often ...
Breaking Medicine News(10 mins):